|
KMID : 0882420110810050562
|
|
Korean Journal of Medicine
2011 Volume.81 No. 5 p.562 ~ p.568
|
|
|
Treatment of Advanced Hodgkin Lymphoma
|
|
Kim Sung-Yong
|
|
|
Abstract
|
|
|
|
The major portion of Hodgkin lymphoma (HL) patients, even at an advanced stage can be cured with optimal initial treatment. ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) is the standard treatment regimen for the advanced stage HL, while Stanford V (doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone) and escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) can be reasonable alternatives for selected patients. Although radiotherapy is the key component in Stanford V regimen, radiotherapy should be applied only at the residual lymphoma in patients who received ABVD and BEACOPP therapy. These three representative treatments for advanced HL have individual advantages and disadvantages, so that the choice of the initial treatment should be dependent on patients’ relapse risk, comorbidity, and age.
|
|
|
KEYWORD
|
|
|
Hodgkin lymphoma, Treatment, Chemotherapy, Radiotherapy
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|